Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 221-203-2 | CAS number: 3030-80-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Skin sensitisation
Administrative data
- Endpoint:
- skin sensitisation: in vivo (LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2017-03-08 to 2017-03-14
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 017
- Report date:
- 2017
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay)
- Version / remarks:
- 22 July 2010
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.42 (Skin Sensitisation: Local Lymph Node Assay)
- Version / remarks:
- 30 May 2008
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Type of study:
- mouse local lymph node assay (LLNA)
Test material
- Reference substance name:
- Zinc di(benzimidazol-2-yl) disulphide
- EC Number:
- 221-203-2
- EC Name:
- Zinc di(benzimidazol-2-yl) disulphide
- Cas Number:
- 3030-80-6
- Molecular formula:
- C7H6N2S.1/2Zn
- IUPAC Name:
- 2-{[(1H-1,3-benzodiazol-2-ylsulfanyl)zincio]sulfanyl}-1H-1,3-benzodiazole
- Test material form:
- solid: particulate/powder
Constituent 1
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source and batch No.of test material: OUCHI SHINKO CHEMICAL INDUSTRIAL CO., LTD.; 608011
- Expiration date of the lot/batch: 2018-08-31
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: Keep to the storeroom with suitable ventilation. Avoid fire, direct sunlight and moisture. Store at room temperature.
In vivo test system
Test animals
- Species:
- mouse
- Strain:
- CBA/Ca
- Sex:
- female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: TOXI-COOP ZRT. H-1103, Budapest, Cserkesz u. 90., Hungary
- Females nulliparous and non-pregnant: yes
- Microbiological status of animals, when known: SPF
- Age at study initiation: 10-11 weeks
- Weight at study initiation: 18.1 – 21.6 g
- Housing: groupwise
- Diet: ad libitum, ssniff® Rat/Souris-Elevage E complete diet (ssniff Spezialdiäten GmbH, D-59494 Soest, Germany)
- Water: ad libitum, tap water
- Acclimation period: 14 days
- Indication of any skin lesions: No
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 3
- Humidity (%): 30 – 70
- Photoperiod (hrs dark / hrs light): 12/12
Study design: in vivo (LLNA)
- Vehicle:
- dimethyl sulphoxide
- Concentration:
- 5, 10, 25 %
- No. of animals per dose:
- 4
- Details on study design:
- PRE-SCREEN TESTS:
Two groups of 2 CBA/Ca mice were treated with the appropriate formulations once daily for 3 consecutive days. All animals were observed for any clinical signs of systemic toxicity or local irritation at the application site during the preliminary test. Body weights were recorded prior to the first treatment (on Day 1) and prior to termination (on Day 6). Both ears of each mouse were observed for erythema and scored according to criteria depicted in Table 2. Measurement of ear thickness was taken using digital micrometer on Day 1 (pre-dose), Day 3 (approximately 48 hours after the first dose) and Day 6.
No mortality, significant, treatment related effect on the body weights or any other sign of systemic toxicity were observed. No sign of significant irritation (indicated by an erythema score ≥ 3 and/or an increase of ≥ 25 % of ear thickness observed on any day of measurement) was observed. Loss of hair (located at the top of the head) was observed in the 25 % (w/v) dose group for 1 animal of the 2 as a possible local effect. The symptom was considered not significant since it was observed for 1 animal and on Day 6, only.
MAIN STUDY
INDUCTION
- Frequency of application: once daily for a total of 3 days (days 1, 2 and 3)
- Site of application: The dorsum surface of both ears
- Route of application: epidermal
- Volume applied: 25 µL/ear
- Concentrations: 5 %, 10 % and 25 % in vehicle
Injection of 3H-methyl thymidine (Amersham Pharmacia Biotech, NOTOX Substance 105624)
- Day of injection: 3 days after last treatment (day 6)
- Site of injection: tail vein
- Vehicle: PBS
- Volume injected: 0.25 mL
- Specific radioactivity: 20 µCi/injection
SACRIFICE
- Time schedule: 5 hours after injection of 3H-methyl thymidine
- Method: injection of phenobarbital
TISSUE PROCESSING AND MEASUREMENTS
- Lymph node processed: auricular lymph nodes
- Pooling of lymph nodes: yes
- Measurement of radioactivity: Tri-Carb 3100TR Liquid Scintillation Analyzer
OTHER
The test animals were checked once daily for mortality/viability and at least once a day for toxicity signs. Bodyweight of the test animals was taken on day 1, prior to treatment and on day 6. On day 3 (3 - 4 hours after treatment), the skin reactions were assessed. If possible, skin reactions were graded following the Draize numerical scoring system. Furthermore descriptions of all other (local) effects were recorded. - Positive control substance(s):
- hexyl cinnamic aldehyde (CAS No 101-86-0)
Results and discussion
- Positive control results:
- The positive control group animals were treated with 25 % HCA solution (formulated in AOO) concurrent to the test item treated groups. No mortality, cutaneous reactions or signs of toxicity were observed in the positive control group. The positive control substance induced the appropriate stimulation compared to the relevant control (AOO). The calculated SI value was 21.1.
In vivo (LLNA)
Resultsopen allclose all
- Key result
- Parameter:
- EC3
- Value:
- < 5
- Key result
- Parameter:
- SI
- Value:
- 9.8
- Test group / Remarks:
- 25 %
- Key result
- Parameter:
- SI
- Value:
- 10.1
- Test group / Remarks:
- 10 %
- Key result
- Parameter:
- SI
- Value:
- 4.8
- Test group / Remarks:
- 5 %
- Cellular proliferation data / Observations:
- CELLULAR PROLIFERATION DATA
Visually larger lymph nodes compared to the relevant vehicle controls (AOO or DMSO) were observed in the positive control group and in all test item treated groups. Appearance of the lymph nodes was normal in the negative control groups (AOO or DMSO).
Significant lymphoproliferative response (SI ≥ 3) was observed for the test item at all test concentrations. The observed stimulation index values were 9.8, 10.1 and 4.8 at test item concentrations of 25 %, 10 % and 5 % (w/v), respectively. The response was considered dose-related although no strong linear correlation was observed.
EC3 CALCULATION
EC3 is normally calculated by linear interpolation using data points lying immediately above and below the SI value of 3 on the LLNA dose-response curve. In this test no SI value below 3 was observed (hence no calculation of the EC3 value was possible), but based on the recent test results an EC3 value of < 5 % (w/v) is considered for the test item.
CLINICAL OBSERVATIONS
No mortality or symptoms of systemic toxicity were observed in any treatment group. No sign of irritation (indicated by an erythema score ≥ 3) or any other local effect were observed in any treatment group.
BODY WEIGHTS
No significant, treatment related effect on the body weights was observed in any treatment group. Loss of body weight > 5 % was observed in the DMSO control group only (1 of the 4 animals, 6 % decrease) but the mean body weight did not decrease hence the effect was considered not significant.
Any other information on results incl. tables
Interpretation of observations
A formulation evaluation and a Dose Range Finding test (DRF) were performed to find an appropriate vehicle and the maximum applicable concentration according to the relevant guidelines. Solubility of the test item in vehicles preferred in the LLNA was evaluated using concentration series recommended by the guidelines. Although the test item was soluble in N,N-Dimethylformamide (DMF), in Dimethyl sulfoxide (DMSO) and in Absolute ethanol: water 7:3 (v/v) mixture (EtOH) only partial solubility was observed even at 0.025 % (w/v) concentration.
Based on this the test item was examined in the LLNA as suspension formulation with the aim of testing as high concentrations as possible above the solubility limit. The maximum feasible concentration resulting in an adequately stable and homogeneous formulation (suspension) was 25 % (w/v). Formulations were prepared with DMSO according to the Sponsor’s request. According to results of the DRF, where no adverse effect was observed up to this maximum concentration, the test item was examined in the main test at concentrations of 25 %, 10 % or 5 % (w/v).
Since the test was valid and no confounding effects of irritation or systemic toxicity were observed during the main test, the proliferation values obtained are considered to reflect the real potential of the test item to cause/not cause lymphoproliferation in the Local Lymph Node Assay.
Significantly increased lymphoproliferation (indicated by an SI ≥ 3) compared to the relevant control (DMSO) was noted for Zinc di(benzimidazol-2-yl) disulphide at all applied test concentrations. The observed stimulation index values were 9.8, 10.1 and 4.8 at test item concentrations of 25 %, 10 % and 5 % (w/v), respectively. Dose-related response was considered although no strong linear correlation was observed.
Applicant's summary and conclusion
- Interpretation of results:
- Category 1 (skin sensitising) based on GHS criteria
- Conclusions:
- Under the conditions of the above assay, Zinc di(benzimidazol-2-yl) disulphide tested at the maximum feasible concentration of 25 % (w/v) and also at concentrations of 10 % or 5% (w/v) as suspension formulations in a suitable vehicle (Dimethyl sulfoxide, DMSO) was shown to have skin sensitization potential in the Local Lymph Node Assay.
- Executive summary:
The skin sensitization potential of Zinc di(benzimidazol-2-yl) disulphide was determined following dermal exposure in the Local Lymph Node Assay according to OECD guideline 429. The pooled treatment group approach was used in this test.
The maximum dose selection was performed according to the relevant guidelines and based on results of a formulation evaluation and a Dose Range Finding test (DRF). According to results of the DRF, where no adverse effect was observed up to this maximum concentration, the test item was examined in the main test at concentrations of 25 %, 10 % or 5 % (w/v).
Appropriate positive control (α-Hexylcinnamaldehyde, HCA), furthermore two negative control groups dosed with the vehicles of the test and positive control groups, respectively, were employed. The positive control item [25 % (w/v) HCA in Acetone:Olive oil 4:1 (v/v) mixture, AOO] induced significant stimulation over the relevant control (SI = 21.1) thus confirming the validity of the assay.
No mortality was observed during the main test. No significant, treatment related effect on body weights or any other sign of systemic toxicity were observed in any treatment group. No signs of irritation (monitored by erythema scoring) or any other local effect were observed at the treatment site (ears) in any treatment group.
Significantly increased lymphoproliferation (indicated by an SI ≥ 3) compared to the relevant control (DMSO) was noted for Zinc di(benzimidazol-2-yl) disulphide at all applied test concentrations. The observed stimulation index values were 9.8, 10.1 and 4.8 at test item concentrations of 25 %, 10 % and 5 % (w/v), respectively. Dose-related response was considered although no strong linear correlation was observed.
According to evaluation criteria of the relevant guidelines, the significantly increased lymphoproliferation (indicated by an SI ≥ 3) at the maximum attainable concentration of 25 % (w/v) as well as at lower concentrations are considered as evidence that Zinc di(benzimidazol-2-yl) disulphide is a skin sensitizer.
Chemicals can be classified according to their relative skin-sensitization potency using the EC3 value (dose calculated to induce a stimulation index of 3) which is normally calculated by linear interpolation using data points lying immediately above and below the SI value of 3 on the LLNA dose-response curve according to published method [7]. In this test no SI value below 3 was observed (hence no calculation of the EC3 value was possible), but based on the recent test results an EC3 value of < 5 % (w/v) is considered for the test item.
Under the conditions of the present assay, Zinc di(benzimidazol-2-yl) disulphide tested at the maximum feasible concentration of 25 % (w/v) and also at concentrations of 10 % or 5 % (w/v) as suspension formulations in a suitable vehicle (Dimethyl sulfoxide) was shown to have skin sensitization potential in the Local Lymph Node Assay.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.